Kamada Ltd. Earnings Recaps
Kamada’s shares fell 6.8% after earnings, reflecting investor disappointment with an acknowledged shipment delay that contributed to first-quarter revenue and adjusted EBITDA coming in only in line with expectations rather than showing growth momentum. Despite management's reiteration of full-year guidance and confidence in demand, the market appears skeptical of the outlook given early execution challenges.
Key takeaways
- Reported Q1 revenues and adjusted EBITDA were in line with expectations, not exceeding them, impacted by a temporary shipment delay of a single order.
- Management reaffirmed 2026 annual guidance of $200-$205 million in revenue and $50-$53 million in adjusted EBITDA, targeting double-digit growth solely through organic initiatives.
- Underlying product demand, including increases in U.S. and international sales of key products like KEDRAB and GLASSIA, was highlighted but without clear evidence of acceleration in the quarter.
- Expansion plans include launching additional biosimilars in Israel and growing plasma collection operations to improve vertical integration and cost control.
- Ongoing clinical studies for CYTOGAM and increased market demand for VARIZIG support longer-term growth but have yet to translate into near-term financial upside.
Kamada Ltd. delivered robust performance in Q3 2025, achieving an 11% year-over-year revenue growth and a significant 35% increase in adjusted EBITDA, reinforcing its full-year guidance.
Key takeaways
- Total revenues for the first nine months reached $135.8 million, with adjusted EBITDA at $34.2 million, highlighting strong operational efficiency.
- The company is maintaining its 2025 revenue guidance of $178 million to $182 million and adjusted EBITDA of $40 million to $44 million.
- Growth driven by increased demand for products like KedRAB and GALASIA, alongside strategic marketing initiatives for Cytogam and new biosimilars.
- Active due diligence in potential M&A opportunities, expected to enhance product portfolio and accelerate commercial growth.
- Progress on plasma collection centers in Houston and San Antonio, anticipated to generate $16 million to $20 million annually at full capacity.
Kamada Limited reported strong second-quarter results, with total revenues increasing by 5% year-over-year, driven by a diverse product portfolio and effective cost management. The company raised its adjusted EBITDA guidance, reflecting robust growth prospects.
Key takeaways
- Q2 2025 revenue reached $44.8 million, while first-half revenue totaled $88.8 million, marking an 11% year-over-year increase.
- Adjusted EBITDA rose 20% year-over-year to $10.9 million in Q2, representing a 25% margin.
- The company is expanding its biosimilar pipeline and anticipates notable revenue contributions from new products in the next 5 years.
- FDA approval of a new plasma collection center in Houston boosts capacity, projected to generate $8-10 million annually at full utilization.
- Kamada is actively pursuing business development and M&A opportunities to enhance its product portfolio and drive future growth.